Effect of Captopril on GLS in Duchenne Myodystrophy

NCT06485661 — Early Phase 1, Unknown, 20 participants, Ain Shams University

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

Intermediate Term Effect of Captopril on Left Ventricle Global Longitudinal Strain in Patients With Duchenne Myodystrophy

RegistryNCT06485661
StatusUnknown
PhaseEarly Phase 1
Study typeInterventional; na, single group, masking: none, treatment
Enrollment20 (Estimated)
SponsorAin Shams University (Other)
ConditionsEffect of Drug
InterventionsCaptopril Tablets (Drug)
Datesstart 2024-01-01, primary completion 2024-09-30 (estimated), completion 2024-09-30 (estimated), first posted 2024-07-03, last updated 2024-07-16
Locations1 site in Egypt

Related Papers Related Patents Related Grants Related Experts
All trials for Effect of Drug All trials of Captopril Tablets

-Summary

To outline the intermediate term effect of prescribing Captopril as an add on therapy on Left ventricular functions as measured by Global longitudinal strain in patients with Duchenne myodystrophy (DMD)

Expand all sections  ·  Collapse all

+Detailed description

ACEI slowing down the onset and the progression of dystrophinopathic cardiomyopathy.

To outline the intermediate term effect of prescribing Captopril as an add on therapy on Left ventricular functions as measured by Global longitudinal strain in patients with Duchenne myodystrophy (DMD

+Arms and interventions

ArmTypeInterventionsDescription
Duchenne patients subjected to captoprilOtherDrug: Captopril Tablets
  • Captopril Tablets (Drug): Patients will be given captopril to see effect on global longitudinal strain

+Outcome measures

Primary outcomes

  • The impaired global longitudinal strain will change in echo in the number of participants with duchenne myodystrophy [6 months]: Impaired Global longitudinal strain will be changed in echo after 6 months of treatment with Captopril in patients with duchenne myodystrophy

+Eligibility

Sex: Male, ages: 6 Years to any

Inclusion Criteria:

* Genetically confirmed Duchenne myodystrophy (DMD) patients with abnormal GLS < -18% with minimum age of 6 years old.

Exclusion Criteria:

* Any patient who refuses to sign an informed consent.
* Contraindication to ACEI: hypersensitivity - renal impairment - bilateral renal artery stenosis - aortic valve stenosis - hyperkalemia - hypotension.
* Reduced ejection fraction below 50%.

+Locations (1)

FacilityCityCountryStatus
Ain Shams universityCairoEgyptRecruiting

+Investigators